ClinicalTrials.gov
public full text
Public Domain
A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
BTK participates in a variety of signal transduction of innate and adaptive immunity, and has an important role in cell proliferation, differentiation and apoptosis. The impact of BTK inhibitors on hematological malignancies and autoimmune diseases has been well studied. This project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of refractory ITP.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety of Intranodal ECI-006 in Melanoma Patients#1032452
- A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia#896665
- Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies#843457
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia#1089036
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)#1073757
Record · ID 1074133
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive